CJC1295 (No DAC) + Ipa

5mg/5mg CJC-1295 No DAC with Ipamorelin is a dual-peptide research formulation combining two synthetic peptides commonly studied in growth hormone–related signaling and endocrine pathway research. CJC-1295 No DAC is a growth hormone–releasing hormone analog designed for investigations involving pituitary stimulation and growth hormone pulse signaling, while Ipamorelin is a selective ghrelin receptor agonist frequently studied for its interaction with the GHSR-1a receptor. Together, these compounds are often examined in controlled laboratory models focused on growth hormone release mechanisms, receptor-specific activation, and peptide interaction profiles.

In research environments, this combination is commonly used to study how GHRH analogs and ghrelin receptor agonists may work through separate but complementary pathways. CJC-1295 No DAC is studied for its ability to support growth hormone–releasing hormone receptor activity, while Ipamorelin is evaluated for its selective stimulation of ghrelin receptor pathways involved in pituitary signaling. Because the two peptides act through different receptor systems, researchers often examine the blend for potential synergistic effects on growth hormone secretion patterns and downstream GH/IGF-1 axis activity.

This formulation is also referenced in studies involving endocrine signaling, pituitary response, receptor selectivity, and peptide-based hormone regulation. Researchers may evaluate how the combination influences growth hormone pulse dynamics, cellular signaling responses, and experimental markers associated with neuroendocrine function. The pairing of CJC-1295 No DAC and Ipamorelin makes the formulation useful for exploring how multiple peptide pathways may interact within controlled in vitro or preclinical research models.

Supplied as a 5mg/5mg lyophilized research blend, this formulation supports stable storage, controlled preparation, and consistent handling during laboratory workflows. Lyophilized peptide formats are commonly used to help preserve compound integrity before reconstitution and experimental use. Due to its defined dual-peptide composition, receptor-specific research relevance, and role in endocrine pathway studies, CJC-1295 No DAC with Ipamorelin remains a valuable reference formulation for investigations involving pituitary signaling, growth hormone release, GH/IGF-1 axis regulation, and peptide interaction behavior under controlled research conditions.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Not for human consumption.